Clinical Development

Suven discovery research is focused on discovering and developing new chemical entities (NCEs), which are best in class central nervous system therapies for the treatment of cognitive disorders, major depressive disorders, sleep disorders, psychiatric disorders, pain and inflammation, gastro-intestinal motility disorders. Research targets includes serotonin 6 receptor, serotonin 4 receptor, histamine 3 receptor, Nicotinic acetylcholine (Alpha4beta2) receptor, muscarinic M1 receptor, muscarinic M4 receptor, multimodal (Dopaminergic and seretonergic receptor) and P2X purinoceptor 7 receptor.

About Us

Suven Neurosciences, Inc. (formerly SuvenInc) a Delaware company, a wholly owned subsidiary of Suven Life Sciences Limited, India, is a clinical-stage biopharmaceutical company focused on acquisition, development and commercialization of novel therapeutics for the treatment of neurodegenerative disorders. Suven Life Sciences' discovery research programs are focused on discovering and developing novel pharmaceutical products, which are first in class or best in class CNS therapies through the use of GPCR targets, having world wide patents. Suven has 3 clinical stage compounds, a Phase 2 initiated candidate SUVN-502, Phase 1 completed candidate SUVN-G3031 and Phase 1 initiated candidate SUVN-D-4010 for Alzheimer’s disease and Schizophrenia. In addition, the Company has Ten (10) internally-discovered therapeutic drug candidates currently in pre-clinical stage of development targeting conditions such as ADHD, dementia, depression, Huntington’s disease, Parkinson’s disease and pain.

Health for Patients and value for Partners

View Our Mission

Press Release

SuvenInc is presenting at Biotech Showcase™ 2017 on 11th January and attending 35th Annual J.P. Morgan Healthcare Conference at San Francisco

  • 1100 Cornwall Road, Suite 110,
  • Monmouth Junction,
  • New Jersey 08852,USA
  • © 2018 Suven Neurosciences, Inc.